Results 61 to 70 of about 2,131 (185)

Long-term safety, tolerability, and efficacy of fremanezumab in migraine:A randomized study

, 2020
OBJECTIVE: To assess the long-term safety, tolerability, and efficacy of fremanezumab, a fully humanized monoclonal antibody approved for the preventive treatment of migraine.
Yeung, Paul P., Goadsby, Peter J.; id_orcid, Yang, Ronghua, Cohen, Joshua M., Dodick, David W., Silberstein, Stephen D., Ning, Xiaoping, Paul P. Yeung, Peter J. Goadsby, Xiaoping Ning, Ronghua Yang, Stephen D. Silberstein, Joshua M. Cohen, David W. Dodick   +13 more
core   +1 more source

Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis

, 2023
Objective: This study aimed to determine the number needed to treat (NNT), number needed to harm (NNH), and likelihood of being helped or harmed (LHH) in a post hoc analysis of the phase 3b FOCUS trial.
Ashina, Messoud, Mitsikostas, Dimos D., Ning, Xiaoping, Barash, Steve, Diener, Hans-Christoph, Ramirez Campos, Verena   +5 more
core   +3 more sources

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study

Frontiers in Neurology, 2022
IntroductionMonoclonal antibodies (mAbs) showed efficacy in migraine prevention. The aim of this study was to check if baseline clinical parameters and cerebral blood flow (CBF) measured by transcranial Doppler (TCD) may help predict mAbs efficacy ...
Magdalena Nowaczewska, Magdalena Nowaczewska, Marcin Straburzyński, Marta Waliszewska-Prosół, Grzegorz Meder, Joanna Janiak-Kiszka, Wojciech Kaźmierczak   +6 more
doaj   +1 more source

Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment

MedComm, Volume 7, Issue 9, September 2026.
Migraine is a highly prevalent, female‐predominant, and disabling brain disorder shaped by genetic susceptibility, hormonal influences, modifiable attack factors, and comorbidity‐related progression. This review integrates current evidence on migraine epidemiology, phase‐specific neurovascular and neuroglial mechanisms, including CGRP signaling and ...
Weiwei Lu, Yuan Zhang, Chen Shi, Yu Tao, Shaoxin Li, Yufang Sun, Fuhai Ji, Dongsheng Jiang, Terrance P. Snutch, Jin Tao   +9 more
wiley   +1 more source

Fremanezumab in the prevention of migraine: a profile of its use

, 2019
Compliance with ethical standards Funding: The preparation of this review was not supported by any external funding. Conflicts of interest: Y. N. Lamb is a salaried employee of Adis International Ltd./Springer Nature, is responsible for the article ...
Yvette Lamb (6930427)
core   +1 more source

Data_Sheet_1_Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan.PDF

, 2023
BackgroundThe effectiveness of fremanezumab in treating migraine has been demonstrated in randomized controlled trials. However, real-world study results are still limited.MethodsWe conducted a single-center, observational study that included patients ...
Yasuo Haruyama (283964), Shiho Suzuki (115477), Koichi Hirata (52794), Keisuke Suzuki (777222), Tomohiko Shiina (10937827)   +4 more
core   +1 more source

Migraine and Work‐Disability: New Treatments Reduce Work‐Related Burden Among Migraine Population

European Journal of Neurology, Volume 33, Issue 9, September 2026.
Migraine is a disabling disease with a substantial hidden work‐related burden, often underestimated by standard patient‐reported outcome measures. In this study, patients treated with anti‐CGRP monoclonal antibodies showed a reduction in monthly migraine days and acute medication use, together with an improvement in work‐related burden as measured by ...
Danilo Antonio Montisano, Gloria Vaghi, Claudia Altamura, Alessandra Parisi, Roberto De Icco, Marilena Marcosano, Alessia Marcassoli, Erika Guastafierro, Michele Corrado, Domenico D'Amico, Grazia Sances, Fabrizio Vernieri, Cristina Tassorelli, Alberto Raggi, Licia Grazzi   +14 more
wiley   +1 more source

Online interest in calcitonin gene‐related peptide‐therapies: An infodemiology study using Google trends

Headache: The Journal of Head and Face Pain, Volume 66, Issue 8, Page 1788-1800, September 2026.
Abstract Objective To evaluate changes in public interest in calcitonin gene‐related peptide therapies associated with major product lifecycle milestones using online search data from the United States and Europe. Background Calcitonin gene‐related peptide therapies have transformed migraine treatment, but the impact of key product lifecycle milestones
Bradley Ong, Jad El Ahdab, Nicolas Thompson, Maithili Bhagat, John Ney, Allison L. Weathers   +5 more
wiley   +1 more source

Efficacy of fremanezumab in patients with chronic migraine and concomitant depression

Background. Migraine is a common chronic disorder that ranks third in the disability-adjusted life years among nervous system disorders. It is well known that migraine is strongly associated with the depression/anxiety disorders; there is overwhelming ...
A.Y. Timokhovich, A.V. Berdnikova, N.V. Latysheva   +2 more
core   +1 more source

The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness. [PDF]

Neurol Sci
Introduction: Migraine burden encompasses social, economic, and functional burden; most notably in individuals with either chronic or high-frequency episodic migraine (CM, HFEM).
Vernieri F, Ambrosini A, Bartolini M, Cevoli S, Coppola G, D'Onofrio F, De Simone R, Granato A, Guerzoni S, Prudenzano MP, Rainero I, Rao R, Tassorelli C, Kokturk P, Cepparulo M.   +14 more
europepmc   +2 more sources